Financials
Financial year 2026
HM Pharma from Pittem, company number BE0765423931, closed financial year 2026 with a result of € 67,980 after tax. For that financial year HM Pharma recorded a gross margin of € 192,466 and equity of € 354,554. Compared with financial year 2025, the result moved from € 73,689 to € 67,980. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 28, 2026.
€ 354,554
▲ 24% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 67,980
▼ 8% vs 2025
Profit after tax over the fiscal year.
€ 181,683
▲ 31% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € 353,554.
People and assets in 2026
€ 83,185
▲ 10% vs 2025
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 32,818
▲ 6% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 774,919
▲ € 727,567 vs 2025
€ 70,854 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 101,495
▲ 52% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 18,085
▼ 30% vs 2025
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 171,578 | € 184,268 | € 196,403 | € 192,466 | ▼ 2% |
| Profit after taxes | € 71,136 | € 71,878 | € 73,689 | € 67,980 | ▼ 8% |
| Equity | € 141,008 | € 212,885 | € 286,574 | € 354,554 | ▲ 24% |
| Total debts | € 186,397 | € 196,975 | € 150,953 | € 899,919 | ▲ € 748,965 |
| Cash | € 19,967 | € 104,073 | € 138,746 | € 181,683 | ▲ 31% |
| Land & buildings | € 88,976 | € 78,069 | € 67,163 | € 63,536 | ▼ 5% |
| Retained profit | € 140,008 | € 211,885 | € 285,574 | € 353,554 | ▲ 24% |
| Bank debt | € 77,585 | € 66,974 | € 47,352 | € 774,919 | ▲ € 727,567 |
| Balance sheet total | € 327,404 | € 409,860 | € 437,528 | € 1,254,473 | ▲ 187% |
Key figures of HM Pharma, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to HM Pharma?
What happened at HM Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 67,980 (▼ 8% vs 2025). Source: NBB ↗
- New establishment in Oudenburg. KBO
- Start of the company according to the CBE. KBO
In short
From € 71,136 profit in 2023 to € 67,980 profit in 2026.
Paid € 90,218 in corporate taxes since 2023.
Best year ever: 2025, with € 73,689 profit.
Management
Behind HM Pharma are Hanne Martens and Emiel Vandewalle. It owns 100% of AKV Pharma itself.
Directors
According to the 2026 annual accounts
Hanne Martens
Director
Emiel Vandewalle
Director
Establishments
Establishment units
Physical locations of this company
Koolskampstraat 69
8740 Pittem
Marktstraat 32-34
8460 Oudenburg
Active since 1 April 2021
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0765.423.931
- VAT number
- BE 0765.423.931
- Registered office
- Koolskampstraat 69, 8740 Pittem
- Names & denominations
- HM Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 March 2021
- Peppol
- Active · Active since 2 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten